Sutro Biopharma

Sutro Biopharma: Focused on developing next generation antibody drug conjugates (ADCs) and multi-specific antibody-based therapeutics for cancer therapy. The company’s discovery and development efforts are driven by its scalable cell-free protein expression platform (Xpress CF) that enables rapid and systematic evaluation of protein structure-activity relationships. Sutro has three wholly-owned ADCs that are on clinical pathways and three high value collaborations with BMS, Merck, and EMD Serono. STRO-001, anti-CD74 ADC, for multiple myeloma and lymphomas is in Phase 1 and showed encouraging initial safety data at EHA & ASH 2019 – additional NHL cohort data will be presented at ASH 2020 and a dose expansion of Ph 1 expected to begin enrolling 1H21. STRO-002 for ovarian and endometrial cancer is also in a Phase 1 trial. At the AACR-NCI-EORTC conference in October 2019, STRO-002 data showed it was well tolerated and demonstrated it’s clinically efficacious at multiple doses (starting at 2.9 mg/kg). Additional Phase 1 data expected during a KOL in 4Q20 and dose-expansion of Ph 1 trial is expected to begin enrolling in 4Q20.
Sector/Industry:
Healthcare/Biotechnology
Characteristics:
Based in...
US - Pacific
Clinical Stage
Phase l or ll
Disease Space
Autoimmune, Infectious Disease, Oncology
Industry
Biotechnology
Listing
Public, USA
Market Cap
500MM - 1B
Therapeutic Modalities
Antibodies, Platform Technology
Website:
Address:
310 Utah Ave
Suite 150
South San Francisco, CA 94080
United States

Company Participants at Sutro Biopharma STRO-002 Data Virtual KOL Event 2020

  • Annie Chang
  • Arturo Molina, MD, MS, FACP, Chief Medical Officer
  • Bill Newell, Chief Executive Officer
  • Edward Albini, Chief Financial Officer
  • Trevor Hallam, Ph.D., Chief Scientific Officer

Top 10 Holders of Sutro Biopharma, Inc.

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
Ecor1 Capital LLC 13.48 3,113,617 85.75 13F 9/30/20
BVF, Inc. 13.37 3,087,195 85.02 13F 9/30/20
BVF Partners LP 5.20 2,368,392 65.23 Stakes 5/22/20
Franklin Advisers, Inc. 9.33 2,155,239 59.36 Funds 12/31/20
RA Capital Management LP 9.17 2,118,212 58.34 13F 9/30/20
Ridgeback Capital Management LP 8.73 2,014,687 55.48 Stakes 8/13/20
Eventide Asset Management LLC 8.60 1,985,975 54.69 13F 9/30/20
SV Health Investors LLC 7.90 1,824,542 50.25 13F 9/30/20
The Vanguard Group, Inc. 7.54 1,742,023 47.98 Funds 12/31/20
Baillie Gifford & Co. 7.34 1,695,654 46.70 13F 9/30/20
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2021 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.